UNAIDS, UNDP release issue brief on TRIPS transition period extensions for LDCs

"The Joint United Nations Programme on HIV/AIDS (UNAIDS) and the United Nations Development Programme (UNDP) today launched a new issue brief" (.pdf), titled "TRIPS transition period extensions for least-developed countries [LDCs]," a UNAIDS press release reports. "The issue brief outlines that failure to extend the transition period for least-developed countries to become fully compliant with the Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) could seriously impede access to lifesaving antiretroviral treatment and other essential medicines for people most in need," the press release notes, adding, "In the issue brief, UNAIDS and UNDP urge [World Trade Organization (WTO)] members to give urgent consideration to the continued special needs and requirements of LDCs in respect of their social and economic development" (2/26).


http://www.kaiserhealthnews.orgThis article was reprinted from kaiserhealthnews.org with permission from the Henry J. Kaiser Family Foundation. Kaiser Health News, an editorially independent news service, is a program of the Kaiser Family Foundation, a nonpartisan health care policy research organization unaffiliated with Kaiser Permanente.

 

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Affordability and supply remain critical to the success of long-lasting HIV drug